US 11,969,433 B2
Compositions and methods for muscle regeneration using prostaglandin E2
Helen M. Blau, Stanford, CA (US); Andrew Tri Van Ho, Stanford, CA (US); and Adelaida R. Palla, Stanford, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US)
Filed on Aug. 22, 2019, as Appl. No. 16/548,531.
Application 16/548,531 is a continuation of application No. 15/891,278, filed on Feb. 7, 2018, granted, now 10,449,205.
Application 15/891,278 is a continuation of application No. 15/498,293, filed on Apr. 26, 2017, granted, now 9,918,994, issued on Mar. 20, 2018.
Application 15/498,293 is a continuation of application No. PCT/US2017/020650, filed on Mar. 3, 2017.
Claims priority of provisional application 62/348,116, filed on Jun. 9, 2016.
Claims priority of provisional application 62/303,979, filed on Mar. 4, 2016.
Prior Publication US 2020/0147103 A1, May 14, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/34 (2015.01); A61K 31/5575 (2006.01); C12N 5/077 (2010.01); A61P 9/10 (2006.01); A61P 21/00 (2006.01)
CPC A61K 31/5575 (2013.01) [A61K 35/34 (2013.01); C12N 5/0658 (2013.01); A61P 9/10 (2018.01); A61P 21/00 (2018.01); C12N 2501/02 (2013.01)] 7 Claims
 
1. A method of treating muscle damage, muscle injury, or muscle atrophy in a subject having spinal muscular atrophy, said method comprising administering a composition comprising a 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitor to said subject in an amount effective to inhibit 15-PGDH, thereby treating said muscle damage, muscle injury, or muscle atrophy in said subject having spinal muscular atrophy.